Krystal(US:KRYS) Globenewswire·2024-05-15 11:00Core Insights - Krystal Biotech, Inc. will present new preclinical data on respiratory genetic medicine candidates KB407 and KB408 at the ATS 2024 International Conference from May 17-22, 2024 [1] Group 1: Product Information - KB407 is designed for the treatment of cystic fibrosis and encodes two full-length copies of CFTR, while KB408 targets alpha-1 antitrypsin deficiency (AATD) and encodes two full-length copies of alpha-1 antitrypsin [2] - Both KB407 and KB408 are currently undergoing Phase 1 studies [3] Group 2: Presentation Details - The poster presentation for KB408 will cover a murine toxicology study and is scheduled for May 20, 2024, from 11:30 AM to 1:15 PM PT [3] - The poster presentation for KB407 will evaluate its efficacy in healthy and patient-derived airway cells and is set for May 21, 2024, from 11:30 AM to 1:15 PM PT [3] Group 3: Company Overview - Krystal Biotech is a commercial-stage biotechnology company focused on genetic medicines for diseases with high unmet medical needs, with its first product VYJUVEK® being the first FDA-approved redosable gene therapy for dystrophic epidermolysis bullosa [4] - The company is advancing a diverse pipeline of investigational genetic medicines across various therapeutic areas including respiratory, oncology, dermatology, ophthalmology, and aesthetics [4]